Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Solute carrier family 22 member 17 (SLC22A17), also known as 24p3 receptor, Lipocalin-2 receptor, and several other aliases, is a multi-pass membrane protein classified as both a transporter and a receptor. It binds to the iron-carrying protein lipocalin-2 (LCN2/NGAL), mediating iron uptake or efflux depending on LCN2's iron status. SLC22A17 plays essential roles in iron homeostasis, cell differentiation, apoptosis regulation, and the modulation of inflammatory processes. It is expressed in various tissues and has been implicated in cancers (notably as a biomarker in lung cancer), as well as inflammatory conditions. Currently, there are no approved drugs that specifically target SLC22A17, but its role in disease and physiologic regulation makes it a potential therapeutic target[1][2][9].
Regulates iron import/export via binding to the iron-carrying protein lipocalin-2 (LCN2/NGAL), inducing downstream effects on apoptosis and inflammation (potential mechanism for drug action if targeted)[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Solute carrier family 22 member 17 (SLC22A17).